At a glance
ClinicalIndex Comparison Record- ✓Previously received at least 3 doses of gp120-NefTat/AS01B (GSKSB732461) vaccine in GSK Biologicals-sponsored PRO HIV-002 study
- ✓Able and willing to comply with protocol requirements
- ✕History of HIV-1 or HIV-2 infection
- ✕Any investigational or non-registered product within 30 days prior to study enrollment
- ✕Participation in another investigational HIV vaccine trial between PRO HIV-002 and present study
- ✕Chronic immunosuppressants (prednisone ≥20 mg/day) or immune-modifying drugs in the month before study
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)
In Brief
A Phase 1 clinical trial evaluating Blood sampling for Infection, Human Immunodeficiency Virus and HIV Infections. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the long-term persistence of binding antibody responses against V1V2 and gp120 in subjects who were vaccinated with the envelope glycoprotein 120 (gp120)-negative factor (Nef)Tat/ Adjuvant System 01B (AS01B) (GSKSB732461) vaccine candidate. Other immune parameters like the HIV-specific cluster of differentiation (CD4+) T cell and CD8+ T cell responses will also be evaluated.
Study Details
Timeline
Interventions
Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.